Objective psychosocial function vs. subjective quality-of-life in schizophrenia within 5-years after diagnosis: A study from southern India.


Journal

Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385

Informations de publication

Date de publication:
02 2019
Historique:
received: 29 09 2018
revised: 28 12 2018
accepted: 28 12 2018
pubmed: 7 1 2019
medline: 9 5 2019
entrez: 7 1 2019
Statut: ppublish

Résumé

There is increasing interest from treaters and patients alike in subjective quality-of-life (sQOL) and objective psychosocial function as indices of treatment outcome in studies of schizophrenia. With the emergence of evidence-based treatment protocols (e.g., NIMH-funded Recovery after Initial Schizophrenia Episode Initiative) these outcomes are of particular significance in treatment studies of samples early in the course of their illness. Few studies have investigated demographic, clinical and cognitive factors associated with sQOL in samples early in the course of their illness and compared these factors to objective measures. We administered measures of sQOL or satisfaction with life, and objective psychosocial function to 59 people with schizophrenia within 5-years of diagnosis, along with standardized measures of symptoms and cognition. Results revealed that symptoms, rather than cognitive or demographic variables, were the best independent predictors of both subjective QOL and objective functioning. Positive symptoms were independent predictors of sQOL, while positive and negative symptoms were independent predictors of objective psychosocial status. Depression and cognition were also linked to sQOL. These findings point to the importance of attending to residual positive symptoms early in the treatment of schizophrenia as a means of possibly enhancing both subjective and objective outcome in early course schizophrenia.

Identifiants

pubmed: 30611958
pii: S0165-1781(18)31819-5
doi: 10.1016/j.psychres.2018.12.149
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

419-424

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Matthew M Kurtz (MM)

Department of Psychology and Program in Neuroscience and Behavior, Wesleyan University, Middletown, CT, USA. Electronic address: mkurtz@wesleyan.edu.

Subhashini Gopal (S)

Schizophrenia Research Foundation, Chennai, Tamil Nadu, India.

Sujit John (S)

Schizophrenia Research Foundation, Chennai, Tamil Nadu, India.

R Thara (R)

Schizophrenia Research Foundation, Chennai, Tamil Nadu, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH